Storys zum Thema Health

Folgen
Keine Story zum Thema Health mehr verpassen.
Filtern
  • 15.01.2013 – 15:32

    Biocartis

    Biocartis Strengthens Management Team with General Counsel Life Sciences and Biotechnology

    Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically relevant oncology assays, announced today that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis' Executive Committee and a ...

  • 11.01.2013 – 10:28

    Astellas Pharma Europe Limited

    New Class of Treatment for Overactive Bladder Approved in Europe

    Chertsey, England (ots/PRNewswire) - A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of oral treatment in OAB for over 30 years. Currently around half of patients discontinue OAB treatment after only three ...

  • 08.01.2013 – 13:01

    Shire Pharmaceuticals Group Plc

    Shire Acquires Lotus Tissue Repair, Inc.

    Lexington, Massachusetts (ots/PRNewswire) - - HGT Pipeline Enhanced with Protein Replacement Therapy Being Investigated for the Treatment of Dystrophic Epidermolysis Bullosa Shire plc , announces that it has signed an agreement to acquire Lotus Tissue Repair, Inc. of Cambridge, MA, a privately held biotechnology company developing the first and only protein replacement therapy currently being investigated for the ...

  • 03.01.2013 – 16:10

    Merck Serono

    Merck Serono Announces FDA Approval of Rebif® Rebidose® (interferon beta-1a)

    Geneva (ots/PRNewswire) - Merck Serono, a division of Merck, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) approved Rebif(R) Rebidose(R) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). "Over the past two decades, ...